

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <b>Neff Thomas B</b>			2. Issuer Name and Ticker or Trading Symbol <b>FIBROGEN INC [ FGEN ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>Chief Executive Officer</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>04/03/2019</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O FIBROGEN, INC. 409 ILLINOIS ST.			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) SAN FRANCISCO CA 94158								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/03/2019		M		6,834	A	\$2.9	2,573,308	D	
Common Stock	04/03/2019		S <sup>(1)</sup>		18,200	D	\$54.63 <sup>(2)</sup>	2,555,108	D	
Common Stock	04/03/2019		S <sup>(1)</sup>		200	D	\$55.24 <sup>(3)</sup>	2,554,908	D	
Common Stock	04/03/2019		S <sup>(1)</sup>		1,418	D	\$54.6 <sup>(4)</sup>	71,180	I	By Family Partnership
Common Stock	04/04/2019		M		6,834	A	\$2.9	2,561,742	D	
Common Stock	04/04/2019		S <sup>(1)</sup>		13,900	D	\$53.17 <sup>(5)</sup>	2,547,842	D	
Common Stock	04/04/2019		S <sup>(1)</sup>		2,700	D	\$54.24 <sup>(6)</sup>	2,545,142	D	
Common Stock	04/04/2019		S <sup>(1)</sup>		1,800	D	\$55.14 <sup>(7)</sup>	2,543,342	D	
Common Stock	04/04/2019		S <sup>(1)</sup>		1,118	D	\$53.12 <sup>(8)</sup>	70,062	I	By Family Partnership
Common Stock	04/04/2019		S <sup>(1)</sup>		200	D	\$53.97 <sup>(9)</sup>	69,862	I	By Family Partnership
Common Stock	04/04/2019		S <sup>(1)</sup>		100	D	\$55.13	69,762	I	By Family Partnership
Common Stock								20,000	I	By Spouse
Common Stock								60,946	I	See footnote <sup>(10)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$2.9	04/03/2019		M		6,834		(11)	06/09/2020	Common Stock	6,834	\$0.00	307,548	D	
Stock Option (Right to Buy)	\$2.9	04/04/2019		M		6,834		(11)	06/09/2020	Common Stock	6,834	\$0.00	300,714	D	

Explanation of Responses:

1. Shares sold pursuant to a 10b5-1 plan.
2. The shares were sold at prices ranging from \$54.20 to \$55.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. The shares were sold at prices ranging from \$55.22 to \$55.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. The shares were sold at prices ranging from \$54.29 to \$55.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. The shares were sold at prices ranging from \$52.79 to \$53.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. The shares were sold at prices ranging from \$53.80 to \$54.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
7. The shares were sold at prices ranging from \$54.88 to \$55.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
8. The shares were sold at prices ranging from \$52.77 to \$53.57. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
9. The shares were sold at prices ranging from \$53.80 to \$54.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
10. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
11. Fully vested.

**Remarks:**

/s/ Michael Lowenstein,  
Attorney-in-fact

04/05/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**